Background And Purpose: Although intracranial atherosclerotic disease is often encountered during endovascular treatment for acute vertebrobasilar occlusions, its clinical implication is not well-known. We aimed to evaluate whether intracranial atherosclerotic disease influences the clinical outcomes following endovascular treatment of acute vertebrobasilar occlusive stroke.
Materials And Methods: Fifty-one patients with acute vertebrobasilar occlusive stroke were included. The onset-to-groin puncture time was ≤12 hours, and aspiration- or stent-based thrombectomy was used as the primary treatment method. Following primary endovascular treatment, intracranial atherosclerotic disease (IAD group) was angiographically diagnosed when a fixed focal stenosis was observed at the occlusion site, whereas embolism (embolic group) was diagnosed if no stenosis was observed. Clinical and treatment variables were compared in both groups, and IAD was evaluated as a prognostic factor for clinical outcomes.
Results: The baseline NIHSS score tended to be lower (14 versus 22, = .097) in the IAD group ( = 19) than in the embolic group ( = 32). The procedural time was longer in the IAD group (96 versus 61 minutes, = .002), despite similar rates of TICI 2b-3 (89.5% versus 87.5%, = 1.000). The NIHSS score at 7 days was higher (21 versus 8, = .060) and poor outcomes (mRS 4-6 at 3 months) were more frequent in the IAD group (73.7% versus 43.8%, = .038). IAD (odds ratio, 5.469; 95% CI, 1.09-27.58; = .040) was independently associated with poor outcomes.
Conclusions: An arterial occlusion related to IAD was associated with a longer procedural time and poorer clinical outcome. Further studies are warranted to elucidate the appropriate endovascular strategy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963784 | PMC |
http://dx.doi.org/10.3174/ajnr.A4844 | DOI Listing |
Front Neurol
January 2025
Department of Neurology, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Objective: Recent studies have indicated a close relationship between intracranial arterial stenosis and white matter hyperintensities (WMHs), but few have reported on the correlation between the characteristics of intracranial arterial wall plaques and WMHs. The aim of this study was to comprehensively assess the correlation between intracranial atherosclerosis plaques and WMHs using 3.0T high-resolution magnetic resonance imaging (HR-MRI).
View Article and Find Full Text PDFJ Neurointerv Surg
January 2025
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Background: Drug-coated balloons (DCB) can decrease the incidence of restenosis in the treatment of intracranial atherosclerotic stenosis (ICAS). This study aimed to assess the safety and efficacy of submaximal angioplasty with DCB dilation compared with aggressive angioplasty in patients with symptomatic ICAS.
Methods: This study prospectively and consecutively enrolled patients with symptomatic ICAS who underwent DCB angioplasty between January 2021 and December 2023.
Int J Stroke
January 2025
Medical University of South Carolina, Charleston, SC, USA.
Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.
Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.
Biomedicines
December 2024
Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.
Advances in stroke genetics have highlighted the critical role of rare genetic variants in cerebrovascular diseases, with emerging as a key player in ischemic stroke and Moyamoya disease (MMD). Initially identified as the primary susceptibility gene for MMD, -notably the p.R4810K variant-has been strongly linked to intracranial artery stenosis (ICAS) and various ischemic stroke subtypes, particularly in East Asian populations.
View Article and Find Full Text PDFAJNR Am J Neuroradiol
January 2025
University of Padova (M.C.); University of Bologna (M.O.A.); Department of Radiology (R.C, R.S., L.S.), Azienda Ospedaliero Universitaria (A.O.U.) di Cagliari, Cagliari, Sardegna, Italy; Department of Neurology and Stroke Program (S.C.), University of Maryland School of Medicine, Baltimore, Maryland, United States; CVPath Institute (R.V.), Gaithersburg, Maryland, United States; Department of Radiology (G.DR.), Azienda San Camillo Forlanini, Rome, Lazio, Italy; Department of Epidemiology (D.B.), Erasmus Medical Center, Rotterdam, South Holland, Netherlands; Department of Radiology and Nuclear Medicine (D.B.), Erasmus Medical Center, Rotterdam, South Holland, Netherlands; Mayo Clinic (L.S.), Rochester, Minnesota, United States.
Background: Intracranial atherosclerosis accounts for about 8% of all strokes in Western societies but the influence of arterial calcification on plaque instability is a topic on ongoing debate.
Purpose: Explore the association between the presence and burden of calcium in atherosclerotic plaques among intracranial arteries with the risk of clinical or silent stroke events through a systematic review and meta-analysis.
Data Sources: Adhering to PRISMA guidelines, studies from PubMed and Embase were analyzed up to May 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!